Healthcare and Pharmaceutical Sector

BlossomHill Therapeutics raised $150 million in an upsized initial public offering, selling 9.375 million shares at $16 each on the Nasdaq under the ticker BLSM. The biotech expanded its offering from 7.8 million shares to meet oversubscribed demand. The raise finances a direct challenge to AstraZeneca's standard-of-care lung cancer drug Tagrisso, which brought in more than $7 billion last year. BlossomHill will deploy $70 million to push its lead molecule, BH-30643, through Phase 1/2 trials and into a registrational Phase 2 study. The molecule targets non-small cell lung cancer patients who developed C797S-mediated resistance to third-generation treatments. Competition is fierce. BlossomHill is betting a novel molecular structure can beat established rivals like Tagrisso and Johnson & Johnson’s Rybrevant. The company earmarked another $20 million for an acute myeloid leukemia drug and $5 million to move a pan-KRAS inhibitor into the clinic. Chief Executive Officer Jean Cui previously led Turning Point Therapeutics through a 2019 IPO before Bristol Myers Squibb acquired it for $4.1 billion in 2022. Underwriters can purchase another 1.4 million shares to add $22.5 million to the final proceeds.

Oxford Biomedica shares fell more than 24% after the company slashed its 2026 revenue forecast to between £180 million and £200 million, down from a previous range of £220 million to £240 million. The UK cell and gene therapy specialist operates as a contract development and manufacturing organization, producing complex biological treatments for third-party biotech and pharmaceutical clients rather than selling its own proprietary drugs. Revenue suffered when a major client altered its procurement pathway and pushed back project timelines, alongside broader order deferrals across selected client programs. Integration setbacks worsened the commercial drop. Operational readiness at a newly acquired manufacturing plant in Durham, North Carolina, fell six months behind schedule, delaying client runs and squeezing expected 2026 core EBITDA margins into the mid-single digits. Gross cash fell from £97 million in December to £75 million by the end of June. The slide marked the stock's worst single-day trading performance since June 2013. Despite the short-term guidance cut, management maintained its long-term target of reaching £500 million in annual revenue by 2030.

Seeking Alpha downgraded Novo Nordisk A/S to a Sell rating after falling profits and weak Q2 revenue growth forced the drugmaker to project flat to negative sales growth for 2026. The guidance contrasts sharply with Eli Lilly's robust growth trajectory and expanding pipeline. Semaglutide generated roughly 70% of Novo Nordisk's Q2 revenues, leaving the core business heavily dependent on a single franchise. Patent expiries, manufacturing setbacks, and pipeline disappointments are now eroding the company's first-mover advantage in obesity and diabetes. With no major catalysts on the horizon, the stock faces greater valuation risk over the next six to twelve months than upside.